Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Viridian Therapeutics, Inc.\DE (VRDN) Return on Sales (2016 - 2025)

Viridian Therapeutics, Inc.\DE has reported Return on Sales over the past 12 years, most recently at 895.75% for Q4 2025.

  • Quarterly results put Return on Sales at 895.75% for Q4 2025, up 20799.0% from a year ago — trailing twelve months through Dec 2025 was 4.81% (up 88757.0% YoY), and the annual figure for FY2025 was 4.81%, up 88802.0%.
  • Return on Sales for Q4 2025 was 895.75% at Viridian Therapeutics, Inc.\DE, down from 0.5% in the prior quarter.
  • Over the last five years, Return on Sales for VRDN hit a ceiling of 0.5% in Q3 2025 and a floor of 1343.13% in Q2 2025.
  • Median Return on Sales over the past 5 years was 668.07% (2023), compared with a mean of 549.55%.
  • Biggest five-year swings in Return on Sales: tumbled -64956bps in 2023 and later surged 88897bps in 2025.
  • Viridian Therapeutics, Inc.\DE's Return on Sales stood at 135.26% in 2021, then crashed by -222bps to 436.05% in 2022, then crashed by -112bps to 925.93% in 2023, then fell by -19bps to 1103.74% in 2024, then increased by 19bps to 895.75% in 2025.
  • The last three reported values for Return on Sales were 895.75% (Q4 2025), 0.5% (Q3 2025), and 1343.13% (Q2 2025) per Business Quant data.